Unyango Lwaziswa Kwangoko kuNyango loMhlaza wamabele lunika ithemba

A BAMBA FreeRelease | eTurboNews | eTN
IAvatar kaLinda Hohnholz
Ibhalwe ngu Linda Hohnholz

Ehlabathini lonke, i-R&D kumhlaza wamabele kuzo zonke iindlela zayo ikhula ngokuthe chu ngesantya esibalulekileyo kule minyaka idlulileyo kwaye iya kuqhubeka kwiminyaka ezayo. Umhlaza wamabele ngowona mhlaza uxhaphakileyo kwihlabathi kwaye ngowona mhlaza uxhaphakileyo kwabasetyhini kwihlabathi liphela.

I-epidermal growth factor receptor 2-positive (HER2+) yomhlaza wamabele imalunga ne-20% yezehlo zomhlaza wamabele kwaye ngokwembali yayinxulunyaniswa ne-prognosis embi ngokungabikho konyango olusebenzayo. Ukuqonda ukuba ukwazisa unyango olujoliswe kwi-HER2 ngaphambili kwisicwangciso sokulawula isifo kunokuphucula ukusinda okungenasifo (DFS) kwenze imarike enkulu yonyango olujoliswe kwi-HER2. Namhlanje, i-HER2+ izigulana zomhlaza wamabele ziphila ixesha elide kunye nesifo sazo, ngenxa yezicwangciso ezimiselweyo zokulawula izifo zisebenzisa iirejimeni. Ngokutsho koPhando lweMarike yeStats i-HER2+ market iqikelelwa ukuba iza kukhula ukuya kutsho kwi-12.1B yeedola ngo-2030, kwi-Compound Annual Growth Rate (CAGR) ye-1.5%. Ingxelo evela kuMordor Intelligence yongeze ukuba imakethi yonyango lomhlaza webele kulindeleke ukuba ikhule kwi-CAGR ye-8.3% ngexesha lokuqikelela, i-2022-2027. 

Ingxelo yathi: “Ngenxa yokuqhambuka kwe-COVID-19, imakethi ijongene nokudodobala okuncinci ngenxa yokulibaziseka koxilongo, ukunqongophala kwamachiza, kunye nokungafumaneki kwabasebenzi bezempilo. Umzekelo, ngokwenqaku elipapashwe kwiNethiwekhi ye-JAMA ngo-Agasti ka-2020, bekukho ukwehla okukhulu kuxilongo lomhlaza webele (malunga ne-51.8%) e-United States ukusuka nge-1 kaMatshi 2020 ukuya kwi-18 ka-Epreli 2020. Ke ngoko. , ukulibaziseka kokuxilongwa komhlaza webele kuye kwaba nefuthe kunyango olufanayo. Ke, ubhubhani we-COVID-19 ube nefuthe elibi kwimakethi yonyango lomhlaza wamabele kwinqanaba layo lokuqala. Nangona kunjalo, imakethi kulindeleke ukuba ifumane amandla kule minyaka izayo njengoko unyango luphinda luqaliswe kwihlabathi liphela. ” Iinkampani ezisebenzayo ze-biotech kunye ne-pharma kwiimarike kule veki ziquka i-Oncolytics Biotech® Inc., i-Clovis Oncology, Inc., i-Belite Bio Inc., i-Endo International plc, i-Pfizer Inc.

Uphando lweMarike yeStats luqhubekile: “Ngaphezu koko, ezona zinto zikhuthaza ukukhula kwemarike kukwanda kweziganeko kunye nezinga lokuxhaphaka komhlaza wamabele kwihlabathi liphela, ukonyusa utyalo-mali kuphando nakuphuhliso, kunye nenkqubela phambili kwibhayoloji yomhlaza kunye nekhemesti ekhuthaza uphuhliso lwamachiza. Amanani aphezulu kunye nenqanaba lokuxhaphaka komhlaza wamabele kwihlabathi liphela yeyona nto iqhuba ukukhula kwemarike. Ngaphakathi kuMntla Merika, iUnited States kulindeleke ukuba ilawule imarike yonke kulo lonke ixesha loqikelelo. Ezona zinto ziphembelela ukukhula kwentengiso kukwanda komthwalo womhlaza wamabele kweli lizwe kunye nokunyuka kolwazi malunga nomhlaza wamabele kunye nokunyuka kwemveliso. ”

I-Oncolytics Biotech® kunye ne-SOLTI Banikezela ngeDatha eNtsha yeKlinikhi yeBiomarker ebonisa amandla kaPelareorep okuphucula ukuchazwa kwezigulana zomhlaza webele kwiNtlanganiso yoMhlaza webele we-ESMO-Oncolytics Biotech® kunye ne-SOLTI-Innovative Cancer Research namhlanje ibhengeze idatha entsha yekliniki ye-biomarker ebonisa iziphumo, i-immunotherapeueupeutic i-checkpoint inhibition, kunye namandla okuphucula imbonakalo yezigulane ezine-HR +/HER2- umhlaza webele. Idatha, efakwe kwinkcazo yepowusta kwi-2022 ye-European Society ye-Medical Oncology (ESMO) iNtlanganiso yoMhlaza weBreast, ivela kwi-cohorts 1 kunye ne-2 ye-AWARE-1 ​​i-window-of-opportunity study kwizigulane zomhlaza webele zakuqala.

Izigulane kwi-AWARE-1 ​​yokuqala yamaqela amabini aphathwa nge-pelareorep kunye ne-aromatase inhibitor letrozole ngaphandle (i-cohort 1), okanye kunye (iqela le-2), i-PD-L1 checkpoint inhibitor atezolizumab malunga neentsuku ze-21 ngaphambi kokuhlinzwa kokuhlinzwa kwamathambo abo. I-Cohorts 1 kunye ne-2 ye-AWARE-1 ​​izigulane ezibhalise ngokukodwa nge-HR + / HER2- isifo, i-subtype yomhlaza webele ukuba i-Oncolytics izimisele ukuyihlola kwisifundo sokubhalisa esizayo. Iziphumo ezixelwe ngaphambili zibonise ukuba i-AWARE-1 ​​idibene nesiphelo sayo sokuqala sokuguqulela, kunye neqela le-2 elifikelela kwiikhrayitheriya zempumelelo ezichazwe kwangaphambili zokunyuka okubangelwa unyango kumanqaku e-CelTIL (ikhonkco kwi-PR). Amanqaku e-CelTIL yimetric yokudumba kwethumba kunye neselula kwaye inxulunyaniswa neziphumo eziphuculweyo zeklinikhi kwizigulana ezinomhlaza wamabele.

"Idatha yamva nje evela kwi-AWARE-1 ​​ibonisa ngakumbi amandla e-pelareorep okuphucula iziphumo zekliniki kwizigulana ezinomhlaza wamabele ngokukwazi ukwenza iiseli ze-T zisebenze kunye nokuhlaziya i-tumor microenvironment," utshilo uThomas Heineman, MD, Ph.D., iGosa eliyiNtloko lezoNyango le-Oncolytics. . "Ngokuqaphelekayo, unyango lwe-pelareorep lonyuse iimpawu zokufa kweseli yethumba kwaye, mhlawumbi ichukumisa ngakumbi, i-100% yezigulana ezivavanywayo ezinyangwa nge-pelareorep zineRisk ethandekayo yokuPhinda kweNqaku (ROR-S) xa kuthelekiswa ne-55% ekuqaleni. Ngokudibeneyo, ezi ziphumo ze-AWARE-1 ​​zamva nje ziseka amandla e-pelareorep okuhlasela amathumba ngeendlela ezininzi.

Malunga nombhali

IAvatar kaLinda Hohnholz

Linda Hohnholz

Umhleli oyintloko we eTurboNews esekwe kwi-eTN HQ.

Bhlisa
Yaziswe ngawo
guest
0 izimvo
Inline feedbacks
Jonga zonke izimvo
0
Ndingazithanda iingcinga zakho, nceda uphawule.x
Yabelana ku...